Ito Yasuo, Mitsufuji Takashi, Asano Yoshio, Shimazu Tomokazu, Kato Yuji, Tanahashi Norio, Maruki Yuichi, Sakai Fumihiko, Yamamoto Toshimasa, Araki Nobuo
Department of Neurology, Saitama Medical University, Japan.
Saitama Neuropsychiatric Institute, Japan.
Intern Med. 2017 Oct 1;56(19):2579-2582. doi: 10.2169/internalmedicine.8865-17. Epub 2017 Sep 6.
Objective Naratriptan has been reported to reduce the frequency of cluster headache. The purpose of this study was to determine whether naratriptan is effective as a prophylactic treatment for cluster headache in Japan. Methods We retrospectively reviewed all 43 patients with cluster headache who received preventive treatment with naratriptan from April 2009 to April 2015. The International Classification of Headache Disorders, 3rd Edition (beta version) (ICHD-3 beta) was used to diagnose cluster headache. This study was conducted at 3 centers (Department of Neurology, Saitama Medical University; Saitama Neuropsychiatric Institute; Saitama Medical University International Medical Center). Patients were recruited from these specialized headache outpatient centers. Naratriptan was taken before the patient went to bed. Results The study population included 30 men (69.8%) and 13 women (30.2%). Twenty-two cases received other preventive treatments (51.2%), while 21 cases only received naratriptan (48.8%). Among the 43 cases, 37 patients (86.0%) achieved an improvement of cluster headache on naratriptan. Conclusion Naratriptan has been suggested as a preventive medicine for cluster headache because of the longer the biological half-life in comparison to other triptans. The internal use of naratriptan 2 hours before attacks appears to achieve a good response in patients with cluster headache.
目的 据报道,那拉曲普坦可降低丛集性头痛的发作频率。本研究的目的是确定那拉曲普坦在日本作为丛集性头痛预防性治疗药物是否有效。方法 我们回顾性分析了2009年4月至2015年4月期间接受那拉曲普坦预防性治疗的43例丛集性头痛患者。采用《国际头痛疾病分类》第3版(beta版)(ICHD - 3 beta)诊断丛集性头痛。本研究在3个中心进行(埼玉医科大学神经内科;埼玉神经精神研究所;埼玉医科大学国际医疗中心)。患者从这些专门的头痛门诊中心招募。那拉曲普坦在患者睡前服用。结果 研究人群包括30名男性(69.8%)和13名女性(30.2%)。22例患者接受了其他预防性治疗(51.2%),而21例患者仅接受那拉曲普坦治疗(48.8%)。在这43例患者中,37例(86.0%)使用那拉曲普坦后丛集性头痛症状得到改善。结论 由于那拉曲普坦的生物半衰期比其他曲坦类药物更长,已被建议作为丛集性头痛的预防药物。在发作前2小时内使用那拉曲普坦似乎能使丛集性头痛患者获得良好反应。